Join
Live feed
·
PRReleasevia Quantisnow
Annexon Inc. logo

Annexon Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington's Disease

ByQuantisnow·Wall Street's wire, on your screen.
ANNX· Annexon Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ANNX (Annexon Inc.) and more on Quantisnow.